Skip to main content

Forschungsseminar Vorlesung von Saskia Schmidt und Victor Dudal

Elucidating the mechanism of methotrexate induced fibrosis An application of in-vitro safety toxicology to a novel type of drug, Saskia Schmidt, PhD Studen Institut für Chemie und Bioanalytik der Hochschule für Life Sciences FHNW und Victor Dudal, CEO Perseo Pharma AG

Liver fibrosis is characterized by the replacement of liver tissue by connective tissue as a result of chronic liver injury. Methotrexate, which is often used in the long-term treatment of rheumatoid arthritis, has been associated with fibrosis in 5% of treated patients. The mechanism by which methotrexate induces fibrosis, is still poorly understood. Thus, we set off to investigate the mechanism of hepatotoxicity of methotrexate in human surrogate cell lines HepaRG and hTERT-HSC. This presentation will detail the thinking process and underlying biological reasons to the development of a novel in-vitro model used to perform some pre-clinical toxicology. This will allow us to give a simple but detailed explanations of some basic immunological concept such as inflammation, immune invasion, the inflammasome and more. We will also briefly explore a new type of compound, nanoparticles.

Datum und Zeit

08.06.2022 12:30 - 13:15 iCal


Hörsaal 02.S.21

FHNW Campus Muttenz, Hofackerstrasse 30, 4132 Muttenz

Veranstaltet durch

Hochschule für Life Sciences


Eintritt frei

Die Referent*innen sind Gäste von

Prof. Dr. Patrick Shahgaldian
Prof. Dr. Patrick Shahgaldian Arbeitsgruppenleiter Molekulare Nanotechnologie
Telefon : +41 61 228 54 87 (Direkt)

FHNW Campus Muttenz

Fachhochschule Nordwestschweiz FHNW Hofackerstrasse 30 4132 Muttenz
Diese Seite teilen: